Table 2.

Fourteen-Day Composite Thrombotic Events and Secondary Outcomes After FEIBA Administration for Perioperative Hemorrhage in LVAD Patients

Primary Composite Outcome	Control (n = 237) (%)	FEIBA (n = 82) (%)	p Value
Thrombotic events	18 (7.6)	9 (11.0)	0.343
Secondary outcomes
Ischemic CVA	4 (1.7)	0 (0.0)	0.576
ICH	3 (1.3)	0 (0.0)	0.572
Combination CVA	1 (0.4)	0 (0.0)	1.000
Pump thrombus	0 (0.0	0 (0.0)	1.000
Pulmonary embolism	1 (0.4)	0 (0.0)	1.000
Deep vein thrombosis	13 (5.5)	9 (11.0)	0.091
GI bleeds	5 (2.1)	1 (1.2)	1.000
Mortality	3 (1.3)	3 (3.7)	0.179

NOTE. Thrombotic events, composite thrombotic outcome of ischemic cerebrovascular accident (iCVA), intracranial hemorrhage (ICH), combination iCVA with hemorrhagic conversion (combination CVA), pump thrombus, pulmonary embolism, and deep venous thrombosis in first 14 days. Categorical variables analyzed by Fischer exact test for n ≤five and chi-squared test for n > five.

Abbreviations: FEIBA, Factor Eight Inhibitor Bypassing Activity; .GI, gastrointestinal.